Drx Choice Maximum Strength Severe Solution
NDC Package 68163-749-08
Package Information
Drx Choice Maximum Strength Severe (acetaminophen, dextromethorphan hbr) solution is ▪do not take more than 6 doses in any 24-hour period▪do not exceed recommended dosage. This formulation utilizes a solution delivery system. Marketed by Raritan Pharmaceuticals, this product is identified by NDC 68163-749 and is authorized under FDA application M012.
Identification & Billing
- RxCUI: 1919076 - acetaminophen 325 MG / dextromethorphan HBr 10 MG in 10 mL Oral Solution
- RxCUI: 1919076 - acetaminophen 32.5 MG/ML / dextromethorphan hydrobromide 1 MG/ML Oral Solution
- RxCUI: 1919076 - acetaminophen 325 MG / dextromethorphan HBr 10 MG per 10 mL Oral Solution
- RxCUI: 1919076 - acetaminophen 650 MG / dextromethorphan HBr 20 MG per 20 mL Oral Solution
- RxCUI: 1919076 - APAP 32.5 MG/ML / Dextromethorphan Hydrobromide 1 MG/ML Oral Solution
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 68163 - Raritan Pharmaceuticals
- 68163-749 - Drx Choice Maximum Strength Severe
- 68163-749-08 - 1 BOTTLE in 1 CARTON / 237 mL in 1 BOTTLE
- 68163-749 - Drx Choice Maximum Strength Severe
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 68163-749-08 identifies a specific commercial package of 1 bottle in 1 carton / 237 ml in 1 bottle of Drx Choice Maximum Strength Severe Cough Plus Sore Throat, a human over the counter drug labeled by Raritan Pharmaceuticals. This solution is formulated for oral use and contains acetaminophen; dextromethorphan hydrobromide as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Raritan Pharmaceuticals on April 24, 2023. The current certification is valid through December 31, 2026.
How is this Raritan Pharmaceuticals product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 68163074908. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.